Table 7 Cost-effectiveness analysis (ACT score) of benralizumab treatment
From: Real-life cost-effectiveness of benralizumab in patients with severe asthma
Period | Mean (SD) per patient | Increase | ||||
|---|---|---|---|---|---|---|
Direct healthcare costs (in €) | Asthma control test | Costs | ACT score | % effectiveness | ||
Score | Effectiveness rate | |||||
Previous 12 months (baseline) | 11,544 (9137) | 13.71 (4.01) | 0.549 (0.151) | 2499 | 7.62 | 0.305 |
At 12 months on benralizumab | 14,043 (3822) | 21.33 (2.21) | 0.853 (0.087) | |||
Cost/effectiveness (per point gained in the ACT) | 327.95 | |||||
Cost of a 3-point increase in the ACT [32] | 983.86 | |||||
Cost of a 7-point increase (from 13 to 20 in the ACT) | 2295.67 | |||||
Cost-effectiveness (% increase in the ACT score) | 8201 | |||||